BACKGROUND: The effects of cholinesterase inhibitors, which increase colonic motility in health, on chronic constipation are unknown. Our aims were to evaluate the efficacy of cholinesterase inhibitors for dysautonomia and chronic constipation and to assess whether acute effects could predict the long term response. METHODS: In this single-blind study, 10 patients with autonomic neuropathy and constipation were treated with placebo (2 weeks), followed by an escalating dose of pyridostigmine to the maximum tolerated dose (i.e., 180-540 mg daily) for 6 weeks. Symptoms and gastrointestinal transit were assessed at 2 and 8 weeks. The acute effects of neostigmine on colonic transit and motility were also assessed. RESULTS: At baseline, 4, 6, and 3 patients had delayed gastric, small intestinal, and colonic transit respectively. Pyridostigmine was well tolerated in most patients, improved symptoms in 4 patients, and accelerated the geometric center for colonic transit at 24 h by > or =0.7 unit in 3 patients. The effects of i.v. neostigmine on colonic transit and compliance predicted (P < 0.05) the effects of pyridostigmine on colonic transit. CONCLUSIONS: Pyridostigmine improves colonic transit and symptoms in some patients with autonomic neuropathy and constipation. The motor response to neostigmine predicted the response to oral pyridostigmine.
BACKGROUND: The effects of cholinesterase inhibitors, which increase colonic motility in health, on chronic constipation are unknown. Our aims were to evaluate the efficacy of cholinesterase inhibitors for dysautonomia and chronic constipation and to assess whether acute effects could predict the long term response. METHODS: In this single-blind study, 10 patients with autonomic neuropathy and constipation were treated with placebo (2 weeks), followed by an escalating dose of pyridostigmine to the maximum tolerated dose (i.e., 180-540 mg daily) for 6 weeks. Symptoms and gastrointestinal transit were assessed at 2 and 8 weeks. The acute effects of neostigmine on colonic transit and motility were also assessed. RESULTS: At baseline, 4, 6, and 3 patients had delayed gastric, small intestinal, and colonic transit respectively. Pyridostigmine was well tolerated in most patients, improved symptoms in 4 patients, and accelerated the geometric center for colonic transit at 24 h by > or =0.7 unit in 3 patients. The effects of i.v. neostigmine on colonic transit and compliance predicted (P < 0.05) the effects of pyridostigmine on colonic transit. CONCLUSIONS: Pyridostigmine improves colonic transit and symptoms in some patients with autonomic neuropathy and constipation. The motor response to neostigmine predicted the response to oral pyridostigmine.
Authors: Michael Camilleri; Sanna McKinzie; Jean Fox; Amy Foxx-Orenstein; Duane Burton; George Thomforde; Kari Baxter; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2004-10 Impact factor: 11.382
Authors: Wolfgang Singer; Paola Sandroni; Tonette L Opfer-Gehrking; Guillermo A Suarez; Caroline M Klein; Stacy Hines; Peter C O'Brien; Jeffrey Slezak; Phillip A Low Journal: Arch Neurol Date: 2006-02-13
Authors: Sara Nullens; Tyler Nelsen; Michael Camilleri; Duane Burton; Deborah Eckert; Johanna Iturrino; Maria Vazquez-Roque; Alan R Zinsmeister Journal: Gut Date: 2011-12-16 Impact factor: 23.059
Authors: Subhankar Chakraborty; Anshuman Desai; Magnus Halland; Duane Burton; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-07-21 Impact factor: 3.598
Authors: Adil E Bharucha; Phillip Low; Michael Camilleri; Erica Veil; Duane Burton; Yogish Kudva; Pankaj Shah; Tonette Gehrking; Alan R Zinsmeister Journal: Gut Date: 2012-06-07 Impact factor: 23.059
Authors: G Parthasarathy; K Ravi; M Camilleri; C Andrews; L A Szarka; P A Low; A R Zinsmeister; A E Bharucha Journal: Neurogastroenterol Motil Date: 2015-09-20 Impact factor: 3.598
Authors: M A Mouchli; M Camilleri; T Lee; G Parthasarathy; P Vijayvargiya; M Halland; A Acosta; A E Bharucha Journal: Neurogastroenterol Motil Date: 2016-02-03 Impact factor: 3.598